Visit your local Alkaloid website

ALKALOID AD Skopje recorded total consolidated sales of €164.2 million in the period January–June 2025, marking a 7% increase compared to the same period of the previous year.

Domestic consolidated sales rose by 19% compared to the first six months of the previous year. Of the total consolidated sales, 34% were generated in North Macedonia while the remaining 66% were realized in foreign markets. Looking at the regional breakdown of foreign sales, 28% were achieved in Southeastern Europe, 19% in Eastern Europe (CIS, Ukraine, etc.), and another 19% in Western Europe (EU and EFTA).

The largest growth among export markets, compared to the previous year, was recorded in sales achieved in the Netherlands, which increased 6.6 times; followed by Austria, where sales increased 5.3 times; Sweden, with a fourfold increase; South Africa, where sales tripled; and Finland, where sales rose 2.8 times. Further notable growth was recorded in Ireland (66%), Georgia (45%), Armenia (23%), Greece (17%), Bosnia and Herzegovina (14%), Germany (14%), Slovenia (10%), Serbia (10%), and Croatia (9%), among others.

Analyzed by product groups, the structure of total consolidated sales is dominated by products from the pharmaceutical segment, which account for 91%, while the segment of chemicals, cosmetics, and herbal products represents 9%. Within the pharmaceutical segment, the largest shares are held by antibiotics with 23%, OTC products with 16%, neurological products with 13%, and cardiological products with 12% of total consolidated sales.

Total investments in fixed assets for the period January – June 2025 amounted to EUR 10 million.

Consolidated earnings before interest, taxes, depreciation, and amortization (EBITDA) amounted to EUR 27.6 million, reflecting a growth of 9%, while consolidated net profit reached €13.9 million, an increase of 4%.

The ALKALOID Group has 3,027 employees, of which 2,269 are in North Macedonia and 758 are employed in affiliated companies abroad.

The share price of ALKALOID AD Skopje on the official market of the Macedonian Stock Exchange during the period January–June 2025 ranged from €390 to €505, with an average of €457 per share, representing an increase of 39% compared to the average share price in the same period of 2024. As of June 30, 2025, the company’s market capitalization amounted to €645.4 million.

On April 1, 2025, at the Shareholders' Assembly of ALKALOID AD Skopje, a Decision was adopted for the payment of dividends for the year 2024 in the amount of €10.2 gross or €9.2 net per share, which represents an increase of 16.67% compared to the dividend paid per share in the previous year. For the dividend payment and personal income tax, the company allocated approximately €14.66 million.

ALKALOID’s management anticipates continued growth throughout 2025, driven by ongoing investments in new production facilities, equipment, and research and development initiatives. These efforts aim to build a competitive product portfolio and expand into new markets. To support these objectives, the company plans to increase its workforce both in North Macedonia and internationally, while consistently enhancing employee expertise, skills, and talent development.